From 1 January 2023, the maximum cost of general prescriptions under the PBS will fall for the first time in the 75-year history of the Pharmaceutical Benefits Scheme (PBS). It’s important that patients understand the changes and how they will affect them.
Over the last 3-6 months, ITP Australia has been working behind the scenes to develop some important patient collateral and materials and add more information across ITPAustralia.org.au.
HAVE YOUR SAY: Submit your letter to us, and we will hand deliver them when we travel to Canberra on Monday 5th September 2022.
The PBAC recommends removing restrictions to make it easier for ALL ITP Patients to access TPORAs.
Missed the ITP Australia Virtual Patient Conference for 2022, or would like to revisit one or more of the presentations? View them here.
The PBAC recommends a change for all listings and brands of Rituximab to be added to the Unrestricted Benefits listings.
Leading ITP clinicians come together and deliver consensus guidelines for the treatment of (ITP) in adult patients.
ITP Australia delivers a number of recommendations to improve treatment access for patients living with Immune Thrombocytopenia.
Review the latest treatment guidelines available for adults living with immune thrombocytopenia in Australia and New Zealand.